LOAC

EFFECT - Longevity Acquisition Corp (0001743858) (Filer)

15-15D - Longevity Acquisition Corp (0001743858) (Filer)

POS AM - Longevity Acquisition Corp (0001743858) (Filer)

25-NSE - Longevity Acquisition Corp (0001743858) (Subject)

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - today announced completion of its merger (“the Merger”) with Longevity Acquisition Corporation ("Longevity")(Nasdaq: LOAC). 4D pharma American Depositary Shares (“ADSs”) are expected to begin trading today on the Nasdaq Global Market under the ticker symbol ‘LBPS.’ Warrants of Longevity assumed by 4D pharma in the Merger are currently expected to begin trading on Nasdaq under the ticker symbol ‘LBPSW’ tomorrow, Tuesday, March 23, 2021. Lo

425 - Longevity Acquisition Corp (0001743858) (Subject)

8-K - Longevity Acquisition Corp (0001743858) (Filer)

425 - Longevity Acquisition Corp (0001743858) (Subject)

NEW YORK, March 18, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today the results of its special meeting of shareholders, which was held on March 17, 2021. At the special meeting, shareholders of the Company approved the merger, including a certain agreement and plan of merger, dated as of October 21, 2020, by and among 4d pharma plc, the Company and Dolphin Merger Sub Limited, and the related agreements and transactions contemplated thereby. About LOAC LOAC is a blank check company, also commonly referred to as a Special Purpose Acquisition Company, or SPAC, formed for the purpose of

425 - Longevity Acquisition Corp (0001743858) (Subject)

425 - Longevity Acquisition Corp (0001743858) (Subject)

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences: Chardan's Virtual 3rd Annual Microbiome Medicines Summit: Monday March 8, 2021 at 11:45 am ET (16:45 GMT). H.C. Wainwright Global Life Sciences Conference: Available on-demand starting Tuesday, March 9, 2021 at 7:00 am ET (12:00 GMT). Oppenheimer’s 31st Annual Healthcare Conference: Tuesday, March 16, 2021 at 8:40 am ET (12:40 GMT). About 4D pharma Founded in February 2014, 4D pharma is a w

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies. “John will be an important addition to 4D pharma’s management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. His deep experience and financial expert

425 - Longevity Acquisition Corp (0001743858) (Subject)

425 - Longevity Acquisition Corp (0001743858) (Subject)

425 - Longevity Acquisition Corp (0001743858) (Subject)

425 - Longevity Acquisition Corp (0001743858) (Subject)

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that the United States Securities and Exchange Commission (“SEC”) has declared effective its registration statements on Form F-4 with respect to the issuance of 4D pharma American Depositary Shares (“ADSs”) to the shareholders of Longevity Acquisition Corporation (NASDAQ: LOAC) (“Longevity”), a NASDAQ-listed special purpose acquisition company (“SPAC”), in connection with the previously announced merger between 4D pharma and Longevity. It is expected that 4D pharma ADS

PRER14A - Longevity Acquisition Corp (0001743858) (Filer)

PRER14A - Longevity Acquisition Corp (0001743858) (Filer)

SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

SC 13G/A - Longevity Acquisition Corp (0001743858) (Subject)

425 - Longevity Acquisition Corp (0001743858) (Subject)